Renal Biomarkers Market, By Biomarkers, By Diagnostic Method, By End Use, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

Description

Renal Biomarkers Market size was valued at US$ 1,650.83 Million in 2025, expanding at a CAGR of 8.55% from 2026 to 2033.

Renal biomarkers are naturally occurring biological substances found in blood, urine, or kidney tissue that help medical professionals understand how well the kidneys are functioning. These markers support the early identification of kidney stress, inflammation, or damage before severe complications develop. Traditional indicators like, serum creatinine and estimated glomerular filtration rate (eGFR) remain widely used, while advanced biomarkers, including NGAL, KIM-1, and cystatin C, are improving the accuracy of kidney disease assessment. Their growing clinical importance is linked to the increasing need for earlier diagnosis, better patient monitoring, and more personalized treatment approaches in nephrology care.

These biomarkers are increasing gradually as healthcare systems worldwide raise attention toward chronic kidney disease, diabetes-related kidney complications, and acute kidney injury. According to the World Health Organization, kidney diseases are becoming a major contributor to global health burden due to rising metabolic and lifestyle-related disorders. In addition, the International Society of Nephrology also reported that millions of people worldwide still face limited access to early kidney diagnostics and treatment services, encouraging stronger investment in advanced testing technologies and preventive healthcare programs.

Renal Biomarkers Market- Market Dynamics

Rising burden of chronic kidney diseases is encouraging demand for early diagnostic solutions.

The cumulative number of people affected by chronic kidney diseases is encouraging demand for renal biomarker skills as early-stage kidney disorders often mature quietly without noticeable signs. Healthcare providers are consequently placing greater importance on diagnostic tools that can identify kidney stress and damage before severe complications arise. According to the International Society of Nephrology, nearly 850 million people worldwide are living with kidney-related diseases, highlighting the growing need for effective screening and disease monitoring solutions. In addition, the UK Kidney Association reported that chronic kidney disease is becoming a major contributor to long-term healthcare burden due to rising diabetes, hypertension, and aging populations.

Healthcare systems and diagnostic companies are increasingly investing in advanced renal testing technologies to support earlier intervention and personalized treatment planning. Companies such as Roche and Abbott Laboratories continue expanding kidney function assessment and biomarker-based diagnostic portfolios to improve disease detection and clinical monitoring capabilities.

Renal Biomarkers Market- Segmentation Analysis:

The Global Renal Biomarkers Market is segmented on the basis of Biomarkers, Diagnostic Method, End Use, and Region.

Within various diagnostic methods, the sector is divided into five categories. The molecular diagnostic is gaining strong attention as it allows the detection of kidney-related molecular changes at an early stage, even before structural damage becomes severe. This makes it highly useful for precision-based kidney disease monitoring and advanced clinical decision-making. Companies are strengthening this direction through innovation in molecular platforms. Thermo Fisher Scientific has expanded its molecular diagnostic solutions, supporting biomarker research and kidney disease-related testing workflows in clinical laboratories. Correspondingly, F. Hoffmann-La Roche is evolving molecular and companion diagnostic technologies that help recover disease detection accuracy and patient monitoring.

Based on end use classification, market is divided into four types. Among those, diagnostic laboratories play a very important role because they serve as the primary testing hubs where most kidney function assessments and biomarker analyses are performed. These laboratories handle large volumes of blood and urine samples, enabling early detection, disease monitoring, and follow-up testing for patients with chronic kidney conditions. From an industry perspective, Siemens Healthineers provides advanced laboratory diagnostics and immunoassay systems that support kidney biomarker analysis in clinical settings. Likewise, Danaher Corporation, through its life sciences and diagnostics businesses, supplies laboratory instruments and testing solutions that enhance biomarker-based disease detection and monitoring.

Renal Biomarkers Market- Geographical Insights

From a geographical perspective, the sector is evolving steadily as healthcare systems across regions increase their focus on early kidney disease detection, preventive diagnostics, and advanced patient monitoring technologies. Among regions, North America is anticipated to register meaningful growth in the market as healthcare systems are placing stronger attention on early kidney disease identification, precision diagnostics, and chronic disease monitoring. The growing burden of diabetes, hypertension, and aging populations has encouraged hospitals and research organizations to adopt advanced biomarker-based testing for earlier intervention and patient management. According to the U.S. Centers for Disease Control and Prevention (CDC), around 37 million American adults are estimated to have chronic kidney disease, while nearly 9 in 10 affected individuals are unaware of their condition, highlighting the need for improved diagnostic screening tools.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) also reported that more than 808,000 people in the United States are living with end-stage kidney disease requiring dialysis or transplantation support. Additionally, CDC surveillance programs continue supporting biomarker-focused kidney research initiatives for earlier disease prediction and treatment planning. Companies such as Quest Diagnostics are expanding renal testing capabilities through specialized laboratory services, supporting broader clinical adoption of kidney biomarker diagnostics across the healthcare network.

China Renal Biomarkers Market- Country Insights

China is witnessing increasing attention toward renal biomarkers as healthcare authorities and medical institutions focus more on early kidney disease screening and chronic disease management. Rising diabetes, hypertension, and aging populations are encouraging hospitals to adopt advanced diagnostic approaches that can identify kidney damage at an earlier stage. According to the Chinese Center for Disease Control and Prevention and the Sixth China Chronic Disease and Risk Factor Surveillance, nearly 82 million adults in China were living with chronic kidney disease, reflecting a substantial need for improved renal monitoring tools.

In another national assessment linked with the Global Burden of Disease Study, China recorded more than 156 million chronic kidney disease cases, showing the growing pressure on healthcare services and diagnostic systems. Companies, including Fosun Pharma, are also expanding diagnostic and biotechnology activities, supporting the development of precision testing and biomarker-based healthcare solutions across China's medical sector.

Renal Biomarkers Market- Competitive Landscape:

Supported by the development of initial disease detection programs and rising awareness concerning chronic kidney disorders, the renal biomarkers sector is viewing continuous improvement from diagnostic corporations, biotechnology firms, and healthcare technology providers. Major contributors such as F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, and Danaher Corporation are focusing on improving diagnostic accuracy, automation competencies, and laboratory efficiency to advance kidney disease nursing.

Companies are progressively growing their portfolios, investing in biomarker validation studies, and enhancing hospital and laboratory partnerships to improve accessibility of renal testing solutions. For example, Quanterix Corporation completed the procurement of Akoya Biosciences to broaden biomarker analysis technologies across blood and tissue applications. Likewise, Quest Diagnostics expanded its renal testing skills through the acquisition of designated clinical laboratory assets from Fresenius Medical Care's Spectra Laboratories.

Recent Developments:

In October 2025, XORTX Therapeutics agreed to acquire Vectus Biosystems' renal anti-fibrotic therapeutic program, including the VB4-P5 compound designed for progressive kidney disease management and future renal biomarker-linked applications. The acquisition strengthened XORTX Therapeutics' renal disease portfolio, supporting the advancement of biomarker-driven therapies for progressive kidney disease treatment.

In April 2025, Novartis announced the acquisition of Regulus Therapeutics to strengthen its renal disease pipeline through farabursen, an investigational microRNA inhibitor developed for autosomal dominant polycystic kidney disease (ADPKD), a major genetic contributor to kidney failure. The acquisition enhances innovation in renal therapeutics, strengthening biomarker-driven kidney disease research and advancing targeted treatment development globally.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RENAL BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Abbott Laboratories
F. Hoffmann-La Roche AG
Siemens Healthineers
Thermo Fisher Scientific Inc.
bioMerieux SA
Beckman Coulter (Danaher Corporation)
Bio-Rad Laboratories Inc.
Randox Laboratories Ltd.
SEKISUI Medical Co., Ltd.
DiaSorin S.p.A.
QIAGEN N.V.
Becton, Dickinson and Company (BD)
PerkinElmer Inc.
Enzo Biochem Inc.
SphingoTec GmbH
EKF Diagnostics Holdings plc
Quanterix Corporation
Novartis
Merck KGaA
Tosoh Bioscience
XORTX Therapeutics
Others

GLOBAL RENAL BIOMARKERS MARKET, BY BIOMARKERS- MARKET ANALYSIS, 2020 - 2033

Kits and reagents
Functional Biomarkers
Serum Creatinine
Blood Urea Nitrogen (BUN)
Estimated Glomerular Filtration Rate (eGFR)
Upregulated Proteins
Kidney Injury Molecule-1 (KIM-1)
Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Cystatin C
Interleukin-18 (IL-18)
Others
Other Novel Biomarkers
microRNA biomarkers
Proteomic/metabolomic markers
Others

GLOBAL RENAL BIOMARKERS MARKET, BY DIAGNOSTIC METHOD- MARKET ANALYSIS, 2020 - 2033

Immunoassays
Clinical Chemistry Assays
Enzyme-Linked Immunosorbent Assay (ELISA)
Molecular Diagnostic
Point-of-Care Testing (POCT) Devices
Others

GLOBAL RENAL BIOMARKERS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033

Diagnostic Laboratories
Hospitals & Clinics
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others

GLOBAL RENAL BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Denmark
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Taiwan
Vietnam
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Iran
Qatar
Rest of MEA

Product Code: ANV6530

1. Renal Biomarkers Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Renal Biomarkers Market Snippet by Biomarkers
- 2.1.2. Renal Biomarkers Market Snippet by Diagnostic Method
- 2.1.3. Renal Biomarkers Market Snippet by End Use
- 2.1.4. Renal Biomarkers Market Snippet by Country
- 2.1.5. Renal Biomarkers Market Snippet by Region
2.2. Competitive Insights

3. Renal Biomarkers Key Market Trends

3.1. Renal Biomarkers Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Renal Biomarkers Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Renal Biomarkers Market Opportunities
3.4. Renal Biomarkers Market Future Trends

4. Renal Biomarkers Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Renal Biomarkers Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Renal Biomarkers Market Landscape

6.1. Renal Biomarkers Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Renal Biomarkers Market - By Biomarkers

7.1. Overview
- 7.1.1. Segment Share Analysis, By Biomarkers, 2025 & 2033 (%)
- 7.1.2. Kits and reagents
- 7.1.3. Functional Biomarkers
  - 7.1.3.1. Serum Creatinine
  - 7.1.3.2. BUN
  - 7.1.3.3. eGFR
- 7.1.4. Upregulated Proteins
  - 7.1.4.1. KIM-1
  - 7.1.4.2. NGAL
  - 7.1.4.3. Cystatin C
  - 7.1.4.4. IL-18
  - 7.1.4.5. Others
- 7.1.5. Other Novel Biomarkers
  - 7.1.5.1. microRNA biomarkers
  - 7.1.5.2. Proteomic/metabolomic markers
- 7.1.6. Others

8. Renal Biomarkers Market - By Diagnostic Method

8.1. Overview
- 8.1.1. Segment Share Analysis, By Diagnostic Method, 2025 & 2033 (%)
- 8.1.2. Immunoassays
- 8.1.3. Clinical Chemistry Assays
- 8.1.4. Enzyme-Linked Immunosorbent Assay (ELISA)
- 8.1.5. Molecular Diagnostic
- 8.1.6. Point-of-Care Testing (POCT) Devices
- 8.1.7. Others

9. Renal Biomarkers Market - By End Use

9.1. Overview
- 9.1.1. Segment Share Analysis, By End Use, 2025 & 2033 (%)
- 9.1.2. Diagnostic Laboratories
- 9.1.3. Hospitals & Clinics
- 9.1.4. Academic & Research Institutes
- 9.1.5. Pharmaceutical & Biotechnology Companies
- 9.1.6. Others

10. Renal Biomarkers Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Renal Biomarkers Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Renal Biomarkers Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.16. Denmark
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.16.3. Denmark Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.16.4. Denmark Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.16.5. Denmark Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.3.17. Rest of Europe
  - 10.3.17.1. Overview
  - 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.17.3. Rest of the Europe Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.3.17.4. Rest of the Europe Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.3.17.5. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Renal Biomarkers Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.15. Taiwan
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.15.3. Taiwan Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.15.4. Taiwan Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.15.5. Taiwan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.16. Vietnam
  - 10.4.16.1. Overview
  - 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.16.3. Vietnam Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.16.4. Vietnam Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.16.5. Vietnam Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.4.17. Rest of APAC
  - 10.4.17.1. Overview
  - 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.17.3. Rest of APAC Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.4.17.4. Rest of APAC Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.4.17.5. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Renal Biomarkers Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Renal Biomarkers Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.13. Iran
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.13.3. Iran Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.13.4. Iran Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.13.5. Iran Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.14. Qatar
  - 10.6.14.1. Overview
  - 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.14.3. Qatar Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.14.4. Qatar Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.14.5. Qatar Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 10.6.15. Rest of MEA
  - 10.6.15.1. Overview
  - 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.15.3. Rest of MEA Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
  - 10.6.15.4. Rest of MEA Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
  - 10.6.15.5. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Renal Biomarkers Industry

11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Abbott Laboratories
- 11.2.2. F. Hoffmann-La Roche AG
- 11.2.3. Siemens Healthineers
- 11.2.4. Thermo Fisher Scientific Inc.
- 11.2.5. bioMerieux SA
- 11.2.6. Beckman Coulter (Danaher Corporation)
- 11.2.7. Bio-Rad Laboratories Inc.
- 11.2.8. Randox Laboratories Ltd.
- 11.2.9. SEKISUI Medical Co., Ltd.
- 11.2.10. DiaSorin S.p.A.
- 11.2.11. QIAGEN N.V.
- 11.2.12. Becton, Dickinson and Company (BD)
- 11.2.13. PerkinElmer Inc.
- 11.2.14. Enzo Biochem Inc.
- 11.2.15. SphingoTec GmbH
- 11.2.16. EKF Diagnostics Holdings plc
- 11.2.17. Quanterix Corporation
- 11.2.18. Novartis
- 11.2.19. Merck KGaA
- 11.2.20. Tosoh Bioscience
- 11.2.21. XORTX Therapeutics
- 11.2.22. Others

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us